Royal Adelaide Hospital

OncoSil Medical Expands Global Reach with New Distribution Deals and Key Regulatory Milestones

4 months ago

OncoSil Medical has secured distribution agreements in the GCC region, Egypt, and Nordic countries, while also obtaining crucial regulatory approvals including UKCA renewal and MDR certification. The company successfully raised $8 million in equity and initiated patient recruitment for the TRIPP-FFX trial, marking significant progress in their mission to advance pancreatic cancer treatment globally.

Nivolumab/Relatlimab Combination Demonstrates Sustained Overall Survival Benefit in Advanced Melanoma

5 months ago

• Extended analysis of the RELATIVITY-047 trial shows nivolumab/relatlimab significantly improves overall survival compared to nivolumab alone in advanced melanoma patients. • Median overall survival reached 51.0 months with the combination therapy versus 34.1 months with nivolumab monotherapy, indicating a substantial survival advantage. • The study also reported improved progression-free survival and melanoma-specific survival with the nivolumab/relatlimab combination. • No new safety signals were identified, reinforcing the combination's manageable safety profile in previously untreated advanced melanoma.

Aethlon Medical Advances Hemopurifier Trial for Solid Tumors Resistant to Anti-PD-1 Therapy

6 months ago

• Aethlon Medical has enrolled the first two patients in its Hemopurifier® trial in Australia, targeting solid tumors unresponsive to anti-PD-1 antibodies. • The trial is a safety, feasibility, and dose-finding study, with two Australian sites now actively enrolling patients and an additional site in India approved. • Strategic cost-cutting measures are being implemented to optimize resource allocation, focusing on high-impact areas of the oncology trial. • The Hemopurifier aims to remove extracellular vesicles (EVs) from the bloodstream, potentially improving response rates to anti-PD-1 therapies.

Aethlon Medical Treats First Patient in Hemopurifier Solid Tumor Trial

6 months ago

• Aethlon Medical has enrolled and treated the first patient in its Australian clinical trial of the Hemopurifier device for solid tumors. • The trial focuses on patients with stable or progressive disease despite anti-PD-1 monotherapy like pembrolizumab or nivolumab. • The Hemopurifier aims to improve response rates by removing tumor-derived extracellular vesicles (EVs) from the bloodstream. • The study's primary endpoint is safety, with secondary measures evaluating changes in EV concentrations and anti-tumor T cell activity.

Engineered Skin Clinical Trial Shows Promise for Severe Burn Treatment

7 months ago

• A clinical trial in Melbourne is testing engineered skin for severe burns, covering at least 20% of the body, using lab-grown skin cells from patient samples. • Early results from the trial indicate positive outcomes, with most wounds closing within two weeks and minimal early scarring observed in treated patients. • The engineered skin, grown in hydrogel sheets, aims to reduce the need for autografts and promote vascularization, offering a potential solution for extensive burns. • Researchers are also exploring methods to improve burn healing, such as using Botox to reduce hypertrophic scarring and cell rejuvenation to speed up graft production.

Aethlon Medical Expands Equity Incentive Plan and Advances Hemopurifier Clinical Trials

8 months ago

• Aethlon Medical increased its equity incentive plan by 3 million shares to attract and retain employees, officers, and directors. • The company received ethics approval for a Hemopurifier clinical trial in cancer patients in India and began patient enrollment in Australia. • Preclinical studies suggest Hemopurifier may improve kidney transplant outcomes by removing harmful substances from preservation fluids. • Aethlon reported a $2.6 million net loss for fiscal Q1 2025 but maintains a cash balance of $9.1 million to support ongoing clinical trials.

Solid Tumor Market Sees Innovation with Aethlon Medical's Hemopurifier Trial and New Immunotherapy Approvals

8 months ago

• Aethlon Medical activates a clinical trial site in Australia for its Hemopurifier device in patients with solid tumors resistant to anti-PD-1 therapies. • The solid tumors market is projected to reach $375.4 billion by 2034, driven by advancements in targeted and immunotherapies. • Immuneering reports promising initial data for IMM-1-104 in pancreatic cancer, showing a 40% objective response rate in early trials. • FDA approves new immunotherapy combinations from AstraZeneca, Merck, and GlaxoSmithKline for advanced endometrial cancer, expanding treatment options.

Aethlon Medical's Hemopurifier Trial Activated at Royal Adelaide Hospital for Solid Tumor Patients

8 months ago

• Aethlon Medical has initiated a clinical trial at Royal Adelaide Hospital to evaluate the Hemopurifier's safety and feasibility in solid tumor patients resistant to anti-PD-1 antibodies. • The trial will assess the Hemopurifier's ability to remove extracellular vesicles (EVs) from the bloodstream, potentially improving response to therapies like pembrolizumab and nivolumab. • This dose-finding study will enroll approximately 18 patients, monitoring adverse events and changes in safety lab tests after Hemopurifier treatment, following initial PD-1 antibody therapy. • Aethlon plans to expand the trial with a second site in Australia and anticipates ethics committee approval for a clinical site in India.